NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37355
Issuer: Viking Therapeutics, Inc.
Exchange: Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 11119 North Torrey Pines Road, Suite 50
San Diego,
CALIFORNIA
92037
Telephone number: 858-550-7810
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Viking Therapeutics, Inc. Warrants expiring 04/13/2021
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o 17 CFR 240.12d2-2(a)(1)
x 17 CFR 240.12d2-2(a)(2)
o 17 CFR 240.12d2-2(a)(3)
o 17 CFR 240.12d2-2(a)(4)
o  Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
o  Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements for the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2021-04-08ByTara PettaDirector
Date NameTitle
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Viking Therapeutics (NASDAQ:VKTX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Viking Therapeutics Charts.
Viking Therapeutics (NASDAQ:VKTX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Viking Therapeutics Charts.

Viking Therapeutics, Inc. News

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Thursday 25 April 2024 (2 weeks ago) • PR Newswire (US)
U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading
Wednesday 24 April 2024 (2 weeks ago) • IH Market News
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Thursday 18 April 2024 (3 weeks ago) • PR Newswire (US)
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Tuesday 26 March 2024 (1 month ago) • PR Newswire (US)
Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Tuesday 5 March 2024 (2 months ago) • PR Newswire (US)
Form 424B5 - Prospectus [Rule 424(b)(5)]
Saturday 2 March 2024 (2 months ago) • Edgar (US Regulatory)
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
Thursday 29 February 2024 (2 months ago) • PR Newswire (US)
Form 424B5 - Prospectus [Rule 424(b)(5)]
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)
Viking Therapeutics Announces Proposed Public Offering of Common Stock
Wednesday 28 February 2024 (2 months ago) • PR Newswire (US)

More Viking Therapeutics, Inc. News Articles